ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed.

1. Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Frontiers in genetics · 2026
   Review
2. Prognostic significance of ALK high expression in SCLC: a 9-year cohort analysis.Frontiers in oncology · 2025
   Article
3. Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation.Thoracic cancer · 2024
   Article
4. Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study.Cancer communications (London, England) · 2024
   Article
5. Alectinib treatment for 2 non-small cell lung carcinoma patients carrying different novelZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
   Article
6. Shifting from Immunohistochemistry to Screen forCancers · 2024
   Article
7. Spitz Melanocytic Tumors: A Fascinating 75-Year Journey.Genes · 2024
   Review
8. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC).Journal of experimental & clinical cancer research : CR · 2023
   Article
9. Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2023
   Article
10. Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer.Discover oncology · 2022
    Article
11. Identification and therapeutic evaluation of ALK rearrangements in non-small-cell lung cancer.The journal of pathology. Clinical research · 2022
    Article
12. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.Virchows Archiv : an international journal of pathology · 2022
    Article
13. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations.Digestive diseases and sciences · 2022
    Article
14. A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2022
    Review
15. Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group.Journal of pathology and translational medicine · 2021
    Review
16. Molecular characterization of lung carcinomas: A study on diagnostic, predictive, and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India.Journal of carcinogenesis · 2021
    Article
17. Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC.International journal of molecular sciences · 2020
    Article
18. Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer.South Asian journal of cancer · 2020
    Article
19. Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.Frontiers in medicine · 2019
    Review
20. Oligometastatic Renal Ewing Sarcoma WithSage open pathology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as